LFWD

Lifeward Ltd. (LFWD) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Lifeward Ltd. is a medical device company specializing in physical rehabilitation and recovery solutions, including the ReWalk exoskeleton for spinal cord injury (SCI) patients, AlterG Anti-Gravity systems, and the ReStore exo-suit. The company operates as a single reporting unit with primary markets in the United States and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 14.7% in Q2 and 10.3% YTD compared to 2024. This was primarily due to the absence of one-time Medicare-related revenue recognized in Q2 2024 and lower MyoCycle sales volume.
• Margin Improvement: Gross margin improved to 43.1% YTD (vs. 34.6% in 2024), driven by the closure of the Fremont manufacturing facility, the transition of AlterG production to a contract manufacturer, and the recent shift of ReWalk production in-house.
• Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $2.78 million in Q2 2025. This was triggered by a sustained decline in the company's stock price, causing market capitalization to fall below the carrying value of the reporting unit.
• Cost Reductions: Operating expenses decreased due to reduced R&D spending (completion of ReWalk 7 and AlterG NEO development) and lower sales/marketing costs (reduced consultant fees and amortization of intangible assets).
• Equity Raises: The company raised capital through a Registered Direct Offering in January 2025, an At-The-Market (ATM) program, and a Public Offering in June 2025, resulting in net financing proceeds of $7.78 million YTD.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern for the next 12 months. Cash resources are estimated to fund operations only into the fourth quarter of 2025. Additional financing is required to sustain operations.
• Nasdaq Compliance: On August 5, 2025, the company received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive days. The company has 180 days (until February 2, 2026) to regain compliance or face potential delisting.
• Operational Highlights:
  • Successfully transitioned ReWalk manufacturing in-house, terminating the agreement with Sanmina Corporation.
  • Received FDA clearance for the ReWalk 7 exoskeleton in April 2025.
  • Secured a favorable Administrative Law Judge ruling establishing Medicare coverage for the ReWalk Personal Exoskeleton as "reasonable and necessary."
  • Appointed Mark Grant as President and CEO and Almog Adar as CFO.
• Risks: Key risks include the inability to secure additional capital, potential delisting from Nasdaq, challenges in scaling in-house manufacturing, and reliance on third-party payors for reimbursement.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for securing additional capital, as current cash ($5.1M) is projected to last only until Q4 2025.
• Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid Nasdaq delisting by February 2026.
• Manufacturing Transition: Assess the operational stability and cost savings realized from the in-house ReWalk manufacturing transition following the termination of the Sanmina contract.
• Reimbursement Progress: Track the volume of Medicare and commercial insurance claims processed following the recent ALJ ruling and the CorLife partnership.
• Dilution Impact: Review the impact of recent equity offerings (January and June 2025) and outstanding warrants on shareholder dilution.